BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 10699907)

  • 1. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
    Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
    Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
    Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
    Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
    J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.
    Berruti A; Terzolo M; Sperone P; Pia A; Della Casa S; Gross DJ; Carnaghi C; Casali P; Porpiglia F; Mantero F; Reimondo G; Angeli A; Dogliotti L
    Endocr Relat Cancer; 2005 Sep; 12(3):657-66. PubMed ID: 16172198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study.
    Bukowski RM; Wolfe M; Levine HS; Crawford DE; Stephens RL; Gaynor E; Harker WG
    J Clin Oncol; 1993 Jan; 11(1):161-5. PubMed ID: 8418229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies.
    Fareau GG; Lopez A; Stava C; Vassilopoulou-Sellin R
    Anticancer Drugs; 2008 Jul; 19(6):637-44. PubMed ID: 18525324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma.
    Spiridonidis CH; Laufman LR; Jones JJ; Gray DJ; Cho CC; Young DC
    Cancer; 1996 Nov; 78(10):2070-7. PubMed ID: 8918399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenocortical carcinoma.
    van Ditzhuijsen CI; van de Weijer R; Haak HR
    Neth J Med; 2007 Feb; 65(2):55-60. PubMed ID: 17379929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
    Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic chemotherapy for adrenocortical carcinoma.
    Dogliotti L; Berruti A; Pia A; Paccotti P; Alì A; Angeli A
    Minerva Endocrinol; 1995 Mar; 20(1):105-9. PubMed ID: 7544429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
    Vaishampayan UN; Faulkner JR; Small EJ; Redman BG; Keiser WL; Petrylak DP; Crawford ED
    Cancer; 2005 Oct; 104(8):1627-32. PubMed ID: 16138364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
    Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E
    Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy in advanced adrenocortical carcinoma.
    Fassnacht M; Terzolo M; Allolio B; Baudin E; Haak H; Berruti A; Welin S; Schade-Brittinger C; Lacroix A; Jarzab B; Sorbye H; Torpy DJ; Stepan V; Schteingart DE; Arlt W; Kroiss M; Leboulleux S; Sperone P; Sundin A; Hermsen I; Hahner S; Willenberg HS; Tabarin A; Quinkler M; de la Fouchardière C; Schlumberger M; Mantero F; Weismann D; Beuschlein F; Gelderblom H; Wilmink H; Sender M; Edgerly M; Kenn W; Fojo T; Müller HH; Skogseid B;
    N Engl J Med; 2012 Jun; 366(23):2189-97. PubMed ID: 22551107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive treatment of adrenocortical carcinoma.
    Terzolo M; Berruti A
    Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):221-6. PubMed ID: 18438168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma.
    Yoh K; Goto K; Ishii G; Niho S; Ohmatsu H; Kubota K; Kakinuma R; Nagai K; Suga M; Nishiwaki Y
    Cancer; 2003 Sep; 98(5):926-31. PubMed ID: 12942558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.